Streetbeat News

NVCT

Nuvectis Pharma, Inc.

https://www.nuvectis.com

Industry

Biotechnology

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Open

5.66

Mkt cap

106M

Volume

35K

High

5.66

P/E Ratio

-4.73

52-wk high

12.10

Low

5.40

Div yield

N/A

52-wk low

4.44

Nuvectis Pharma (NVCT) has formed a hammer chart pattern, suggesting potential support and a possible trend reversal. This is supported by upward revisions in earnings estimates.

Portfolio Pulse from

November 25, 2024 | 4:15 pm

Nuvectis Pharma (NVCT) is highlighted as a strong option for trend investors due to its recent price trend and solid fundamentals. It has passed a short-term trading strategy screen, making it appealing for short-term investors.

Portfolio Pulse from

November 13, 2024 | 3:00 pm

Wall Street analysts predict a significant upside potential of 169.94% for Nuvectis Pharma (NVCT), driven by upward trends in earnings estimate revisions.

Portfolio Pulse from

November 07, 2024 | 4:15 pm

Nuvectis Pharma, Inc. (NASDAQ: NVCT) has released its third quarter 2024 financial results and business highlights, focusing on its progress in developing precision medicines for oncology.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

A new report highlights the potential of Nuvectis Pharma's NXP900 in non-small cell lung cancer (NSCLC) and anticipates upcoming data on NXP800. This positions Nuvectis among precision oncology leaders like Nuvalent and Summit Therapeutics.